000294429 001__ 294429
000294429 005__ 20241129122424.0
000294429 0247_ $$2doi$$a10.1016/j.euf.2024.09.009
000294429 0247_ $$2pmid$$apmid:39505658
000294429 037__ $$aDKFZ-2024-02258
000294429 041__ $$aEnglish
000294429 082__ $$a610
000294429 1001_ $$aBusshoff, Isabelle$$b0
000294429 245__ $$aProstate Biopsy: The Transrectal Approach Is Safe.
000294429 260__ $$aAmsterdam$$bElsevier$$c2024
000294429 3367_ $$2DRIVER$$aarticle
000294429 3367_ $$2DataCite$$aOutput Types/Journal article
000294429 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732879422_19623
000294429 3367_ $$2BibTeX$$aARTICLE
000294429 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294429 3367_ $$00$$2EndNote$$aJournal Article
000294429 500__ $$a#LA:C130# / 2024 Sep;10(5):688-690
000294429 520__ $$aA targeted transrectal biopsy with antibiotic prophylaxis is an effective alternative for patients who do not have access to transperineal biopsy. Transrectal biopsy remains a safe and straightforward method that should continue to be used.
000294429 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000294429 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294429 7001_ $$aHaidl, Friederike$$b1
000294429 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b2$$udkfz
000294429 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b3$$eLast author$$udkfz
000294429 773__ $$0PERI:(DE-600)2861750-2$$a10.1016/j.euf.2024.09.009$$gp. S2405456924001767$$n5$$p688-690$$tEuropean urology focus$$v10$$x2405-4569$$y2024
000294429 909CO $$ooai:inrepo02.dkfz.de:294429$$pVDB
000294429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000294429 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294429 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000294429 9141_ $$y2024
000294429 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL FOCUS : 2022$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000294429 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR UROL FOCUS : 2022$$d2023-10-27
000294429 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000294429 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000294429 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x1
000294429 980__ $$ajournal
000294429 980__ $$aVDB
000294429 980__ $$aI:(DE-He78)E010-20160331
000294429 980__ $$aI:(DE-He78)C130-20160331
000294429 980__ $$aUNRESTRICTED